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Background: PATZ is a transcription factor, whose role in cancer is still under debate.
Results: PATZ interacts with BCL6 and negatively modulates its expression. Consistently, Patz1 knockdown mice showed
up-regulation of BCL6 expression and BCL6-dependent B cell neoplasias.
Conclusion: PATZ is a tumor suppressor that acts by cooperating with BCL6 in its negative autoregulation.
Significance: This work helps in understanding the pathology of BCL6-expressing lymphomas in which BCL6 is not mutated.
ThePATZ1 gene encoding a POZ/AT-hook/Kruppel zinc fin-
ger (PATZ) transcription factor, is considered a cancer-related
gene because of its loss or misexpression in human neoplasias.
As for other POZ/domain andKruppel zinc finger (POK) family
members, the transcriptional activity of PATZ is due to the
POZ-mediated oligomer formation, suggesting that it might be
not a typical transactivator but an architectural transcription
factor, thus functioning either as activator or as repressor
depending on the presence of proteins able to interact with it.
Therefore, to better elucidate PATZ function, we searched for
its molecular partners. By yeast two-hybrid screenings, we
found a specific interaction between PATZ and BCL6, a human
oncogene that plays a key role in germinal center (GC) derived
neoplasias. We demonstrate that PATZ and BCL6 interact in
germinal center-derived B lymphoma cells, through the POZ
domain of PATZ. Moreover, we show that PATZ is able to bind
the BCL6 regulatory region, where BCL6 itself acts as a negative
regulator, and to contribute to negatively modulate its activity.
Consistently, disruption of one or both Patz1 alleles in mice
causes focal expansion of thymus B cells, in which BCL6 is up-
regulated. This phenotype was almost completely rescued by
crossing Patz1!/" with Bcl6!/" mice, indicating a key role for
Bcl6 expression in its development. Finally, a significant num-
ber of Patz1 knock-out mice (both heterozygous and homozy-
gous) also develop BCL6-expressing lymphomas. Therefore, the
disruption of one or bothPatz1 allelesmay favor lymphomagen-
esis by activating the BCL6 pathway.
The PATZ1 gene encodes four main alternative proteins
ranging from 537 to 687 amino acids that contain an N-termi-
nal POZ domain, one or two AT-hooks in the central region,
and four to six C2H2 zinc fingermotifs at the C terminus (1–3).
Both the AT-hooks and the POZ domain are characteristic of
protein factors involved in gene transcription by interacting
with a number of other protein factors. Indeed, PATZ protein,
also known as MAZR, ZNF278, or ZSG, is a transcriptional
regulatory factor that may function either as activator or as
repressor depending upon the cellular context; it has been
reported to either activate or repress c-Myc (1, 2), to activate
mast cell protease 6 (4), and to repress androgen receptor (5)
and CD8 (6) genes.
Different functional and genetic evidences suggest that
PATZ might be directly involved in human tumors. Indeed,
PATZ1 is rearranged and deleted in small round cell sarcoma
(3), and the chromosomal region where it is located (22q12) is
in the human fragile site FRA22B, which suffers loss of
heterozygosity in tumors (7). Increased expression of PATZ1
mRNA has been observed in human malignant neoplasias,
including colorectal (8), breast (9), and testicular (10) tumors.
Moreover, PATZ knockdown by siRNA either blocks the
growth or induces apoptosis of cell lines derived from colorec-
tal cancer or gliomas, respectively (8, 11). However, in testicular
tumors alone, PATZ protein expression has been analyzed,
* This work was supported by Associazione Italiana per la Ricerca sul Cancro
Grant IG 5728 (to M. F.).
1 To whom correspondence may be addressed: Dipartimento di Biologia e
Patologia Cellulare eMolecolare, Università degli Studi di Napoli “Federico
II”, via Pansini, 5, 80131Naples, Italy. Tel.: 39-0817462056; E-mail: chiariot@
unina.it.
2 To whom correspondence may be addressed: Istituto di Endocrinologia ed
Oncologia Sperimentale (IEOS) del CNR, via S. Pansini, 5, 80131, Napoli,
Italy. Tel.: 39-0817463054; Fax: 39-0817463749; E-mail: mfedele@unina.it.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 287, NO. 22, pp. 18308–18317, May 25, 2012
© 2012 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
18308 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 287•NUMBER 22•MAY 25, 2012
 at UNIV OF NAPLES on January 19, 2015
http://www.jbc.org/
Downloaded from 
 at UNIV OF NAPLES on January 19, 2015
http://www.jbc.org/
Downloaded from 
 at UNIV OF NAPLES on January 19, 2015
http://www.jbc.org/
Downloaded from 
demonstrating that it was mislocalized to cytoplasm (10, 12).
Therefore, although PATZ1 is strongly suggested to be a can-
cer-related gene, its role as tumor suppressor or oncogene is
still controversial.
In the present study, starting from a yeast two-hybrid screen-
ing usingPATZ1 full-length cDNAas bait, we demonstrate that
PATZ associates with BCL6,3 a protein that shares with PATZ
the N-terminal POZ domain, responsible for such association,
and is involved in B andT cell development and lymphomagen-
esis (13–15, 38). We show that PATZ participates in BCL6
function by enhancing its activity of transcriptional repressor
on BCL6 promoter in GC-derived lymphoma B cells. We also
show that the knock-down of PATZ in mice causes BCL6-ex-
pressing thymus B cell hyperplasias (that eventually lead to B
cell lymphomas), in which BCL6 is critical for their onset. The
development of BCL6-expressing lymphomas in Patz1 knock-
down mice indicates a potential haploinsufficient tumor sup-
pressor role for the PATZ1 gene, whose disruption may lead to
the lymphomas by activating the BCL6 pathway.
EXPERIMENTAL PROCEDURES
Two-hybrid Analysis—Two-hybrid screens were performed
in yeast using full-length PATZ1 (isoform 4) cDNA as a bait.
Human heart and placenta cDNA libraries (Clontech) were
simultaneously analyzed. A total of about 2 ! 106 clones were
tested for each library, and the specificity of interaction was
assessed as described previously (16).
Plasmids—Full-length and truncated (devoid of the BTB/
POZdomain) cDNAs for the human PATZprotein (isoform 4),
Myc-tagged at their 3"-end, were subcloned into the XbaI-
HindIII sites of the pcDNA3.1 plasmid (Invitrogen). The cDNA
for the human BCL6 protein was subcloned into the EcoRI site
of the pCEFL-HA vector (17), in-frame with the upstream HA
tag. The BCL6i-luc reporter construct was obtained by cloning
the #4.9 to $2.0-kb fragment of the BCL6 promoter into the
pGL3Basic vector as described previously (18).
Protein Extraction, Immunoprecipitation, and Immunoblot
Analysis—Tissues and cells were lysed in buffer containing 1%
Nonidet P-40, 1mmol/liter EDTA, 50mmol/liter Tris-HCl (pH
7.5), and 150 mmol/liter NaCl supplemented with Complete
protease inhibitors (Roche Applied Science). Total proteins
were immunoprecipitated, in the presence or absence of 100
ng/ml ethidium bromide, as described previously (19), or they
were directly resolved in a 10% polyacrylamide gel under dena-
turing conditions and transferred to nitrocellulose filters for
Western blot analyses. Membranes were blocked with 5% BSA
in TBS and incubated with the primary antibodies. The anti-
bodies used were: anti-HA (sc-805), anti-Myc (sc-40), anti-
BCL6 (sc-858), anti-tubulin (sc-5546), anti-vinculin (sc-7649)
(Santa Cruz Biotechnology, Santa Cruz, CA), and anti-PATZ
(polyclonal antibody raised against a conserved peptide recog-
nizing all PATZ isoforms of mouse and human origin).
Cell Cultures and Transcriptional Activity Assays—Raji cells,
originally derived from a Burkitt lymphoma, were cultured in
RPMI 1640 medium adjusted to contain 1.5 g/liter sodium
bicarbonate, 4.5 g/liter glucose, 10 mM HEPES, 1.0 mM sodium
pyruvate, penicillin/streptomycin (Invitrogen/Life Technolo-
gies Italia, Monza, Italy), and 10% FBS (JRH Biosciences,
Lenexa, KS). They were transfected by using the Amaxa
Nucleofector kit V (Lonza, Cologne, Germany) following the
manufacturer’s instructions. COS-1 cells were cultured in
DMEMwith 10%FBS (JRHBiosciences). Theywere transfected
using Lipofectamine Plus reagents (Invitrogen/Life Technolo-
gies Italia) according to the manufacturer’s instructions and
harvested 42 h after transfection. Cell lysates were extracted as
described below and analyzed for luciferase activity. For tran-
scriptional activity assays, a total of 2 ! 106 cells (Raji) were
seeded into each well of a 12-well plate and transiently trans-
fected with 4 !g of BCL6i-luc, 5 !g of HA-BCL6, and 0.25–0.5
!g of PATZ-Myc, together with 1 !g of Renilla and various
amounts of the backbone vectors to keep the total DNA con-
centration constant. Transfection efficiency, normalized for
Renilla expression, was assayed with the Dual-Luciferase sys-
tem (Promega Corp., Madison, WI). All transfection experi-
ments were repeated at least three times. Aliquots of the same
lysates were resolved by SDS-PAGE, transferred to nitrocellu-
lose, and immunoblottedwith anti-BCL6, anti-PATZ, and anti-
vinculin antibodies, as above described.
Chromatin Immunoprecipitation—Chromatin immunopre-
cipitation (ChIP) of Raji cells (%3 ! 107) or chopped spleens
(%1 mg) from Patz1$/$, Patz1$/#, and Patz1#/# mice was
carried out with an acetyl-histone H3 immunoprecipitation
assay kit (Upstate Biotech Millipore, Lake Placid, NY) accord-
ing to themanufacturer’s instructions (19). The antibodies used
are described above. Input DNA and immunoprecipitated
DNA were analyzed by standard PCR for the presence of BCL6
exon 1 and lipoprotein lipase (LPL) promoter sequences using
the following primers: BCL6 exon 1, forward, 5"-CTCTTACT-
CGCCTCTCTAAC-3"; BCL6 exon 1, reverse, 5"-CGGCGGC-
AGCAACAGCAATAATCAC-3"; LPL pr, forward, 5"-ACC-
AAAGTGTCAAGGGCAAC-3"; and LPL pr, reverse,
5"-ATTCCCTAAACCCAGCATCC-3".
We also used real-time quantitative PCR to amplify the BCL6
exon 1, as described below. Primers specific for the glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) gene were used for
normalization of real-time quantitative PCR data. The following
primers were used: qBcl6 exon 1, forward, 5"-TAACACCACAA-
ACTTGCAAAAGG-3"; qBcl6 exon 1, reverse, 5"-CTCCTCGA-
GCTAAATACACAAAAG-3"; qGapdh pr, forward, 5"-TGA-
GTCCTATCCTGGGAACCATCA-3"; qGapdh pr, reverse,
5"-TTTGAAATGTGCACGCACCAAGCG-3".
Generation of Patz1-Knock-out Mice—The Patz1 gene tar-
geting vector was derived from a "&XII phage library of a
129SvJ mouse strain (Stratagene, La Jolla, CA). It was designed
to delete a 2317-bp PstI-XhoI fragment, including the start
codon, the coding regions for the POZ domain, the AT-hook,
and the first four zinc fingers. It was constructed by subcloning
the 5"-flanking region (the SpeI-PstI 3-kb fragment), the neo
cassette, and the 3"-flanking region (the XhoI-XbaI 3.2-kb frag-
ment) into the Bluescript plasmid (Stratagene) that contained a
PacI digestion site inserted at a distance from the multicloning
site. The targeting vector was linearized with PacI before elec-
troporation into embryonic stem (ES) cells (Incyte Genomics,
3 The abbreviations used are: BCL6, B cell lymphoma 6 protein; BCL, B type
lymphoma; GC, germinal center; ES, embryonic stem.
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PaloAlto, CA).Among 700G418-resistant ES clones examined,
10 (1.4%) underwent homologous recombination. Two cor-
rectly targeted ES cell lines were injected into C57Bl/6J blasto-
cysts. Both ES cell lines gave rise to germ line chimeras that
were backcrossed to C57Bl/6J females to obtain Patz1
heterozygous offspring. For Southern blot analysis, tail DNA
samples were digested with StuI and probed with an external 5"
genomic fragment that would detect 9.3- or 8-kb fragments,
corresponding to thewild-type andmutant alleles, respectively.
Themice weremaintained under specific pathogen-free condi-
tions, and all studies were conducted in accordance with Italian
regulations for experimentations on animals.
Isolation of mRNA and Quantitative RT-PCR—Total RNA
was extracted using TRI-reagent solution (Sigma) according to
the manufacturer’s protocol, treated with DNase I (Invitrogen/
Life Technologies Italia), and reverse-transcribed using ran-
dom hexanucleotides as primers and MuLV reverse transcrip-
tase (PerkinElmer Life Sciences) following the manufacturer’s
instructions. For quantitative RT-PCR, each reaction was per-
formed three times in triplicate using the SYBR Green PCR
master mix (Applied Biosystems, Foster City, CA) under the
following conditions: 10 min at 95 °C followed by 40 cycles (15
s at 95 °C and 1min at 60 °C). Subsequently, a dissociation curve
was run to verify amplification specificity. The 2#''CTmethod
was used to calculate relative expression levels (20). Primers
specific for the glucose-6-phosphate dehydrogenase (G6PD)
genewere used for normalization of real-time quantitative PCR
data. The following primers were used: Patz, forward, 5"-GAG-
CTTCCCCGAGCTCAT-3"; Patz, reverse, 5"-CAGATCTCG-
ATGACCGACCT-3"; G6pd, forward, 5"-CAGCGGCAACTA-
AACTCAGA-3"; G6pd, reverse, 5"-TTCCCTCAGGA-
TCCCACAC-3".
Histology and Immunohistochemistry—Dissected tissues
were fixed in 10% formalin and embedded in paraffin by stan-
dard procedures. Mounted sections (5 !m thick) were stained
with hematoxylin and eosin or incubated in a 750-watt micro-
wave oven for 15 min in EDTA (10 mM, ph 8.0) and processed
for immunohistochemistry using the avidin-biotin-peroxidase
LSAB$ kit (Dako, Glostrup, Denmark). Endogenous peroxi-
dase was quenched by incubation in 0.1% sodium azide with
0.3% hydrogen peroxide for 30min at room temperature. Non-
specific binding was blocked by incubation with nonimmune
serum. The antisera were directed toward B220 (RA3-6B2;
SouthernBiotech, Birmingham, AL), CD3 (ab5690; Abcam,
Cambridge, UK), CD79a (ab3121; Abcam), BCL6 (sc-858; Santa
Cruz Biotechnology), and PATZ (described above).
IgH Gene Rearrangement Analysis—Genomic DNA was iso-
lated from tumor masses or normal tissues from control mice,
and Southern blotting was performed with the 32P-labeled
DNA probe PJ3 representing the JH4 region of the IgH locus
(21). A 1.3-kb Pst-1 fragment from theGapdh genewas used for
loading control.
Analysis of Lymphocyte Cell Surface Antigens—Spleens and
thymi removed frommice were dissociated into single cells and
stained for FACS analysis on a FACSCalibur flow cytometer
(BD Biosciences, Buccinasco, Italy) as described previously
(22). All the antibodies used were obtained from Pharmingen.
Statistical Analyses—Kaplan-Meyer survival curves were
used to analyze the percentage of tumor-free mice. Differences
were analyzed by the log rank test. The one-way analysis of
variance followed by Tukey’s multiple comparison test was
used to compare groups of experiments. The statistical signifi-
cant difference was considered when the p value was(0.05.
RESULTS
PATZ Interacts with BCL6—To identify PATZ interacting
proteins, two-hybrid screenings of human heart and placenta
pretransformed libraries were performed. A total of 87 positive
clones (61 and 26 from heart and placenta, respectively) were
isolated. Fourteen clones from heart and two from placenta
libraries contained most of the coding sequence of the BCL6
gene (data not shown). To confirm the interaction between
PATZ and BCL6 in mammalian cells, co-immunoprecipitation
experiments were performed. To this aim, total cell extracts
from COS-1 cells transiently transfected with constructs
encoding Myc-tagged PATZ, Myc-tagged PATZ-'POZ
(devoid of the BTB/POZ domain), and HA-tagged BCL6 (Fig.
1A) were subjected to immunoprecipitation using anti-Myc
antibody. As shown in Fig. 1B, co-precipitation of the BCL6
protein was observedwhen constructs for BCL6 and full-length
PATZwere co-transfected, andnotwhenBCL6was transfected
together with PATZ-'POZ or with the backbone vector.
Therefore, PATZ and BCL6 form a complex in mammalian
cells, and the POZ domain of PATZ is necessary for such
interaction.
FIGURE1. InteractionbetweenPATZandBCL6.A, schematic representationof portions of PATZandBCL6encodedby the transfectedexpression vectors.AT,
AT-hook domain; black ovals, zinc finger motifs. B, co-immunoprecipitation (IP) of transfected PATZ-Myc, PATZ-'POZ-Myc, and HA-BCL6 proteins in COS-1
cells. C, reciprocal co-immunoprecipitation of endogenous PATZ and BCL6 in Raji cells. Immunoprecipitation in the presence of EtBr was performed to control
that it was not mediated by contaminating DNA. Immunoprecipitation with nonspecific IgG was carried out as a control for the specificity of the interaction.
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Next, to ensure that the interaction between PATZ and
BCL6 takes place in a physiological context, endogenous PATZ
and BCL6 were co-immunoprecipitated in Raji cells, deriving
from a Burkitt lymphoma, which is a GC-derived lymphoma
expressing both proteins. The result, shown in Fig. 1C, further
demonstrates that PATZ and BCL6 interact in vivo.
PATZ Is Involved in BCL6 Negative Autoregulation—To
study the functional consequences of the interaction between
PATZ and BCL6, we investigated whether PATZ and BCL6
associate on a BCL6 endogenous target promoter. Previous
experiments demonstrated that the BCL6 gene contains two
non-STAT6 functional BCL6 binding sites located within exon
1 (23). Thus, we examined whether PATZ could bind exon 1 of
the BCL6 gene in vivo. Endogenous PATZ and BCL6 bind to
exon 1 ofBCL6, as determined byChIP experiments inRaji cells
(Fig. 2A). This result was further confirmed in vivo usingmouse
spleens, a tissue that harbors GC cells, where both PATZ and
BCL6 proteins were immunoprecipitated on BCL6 exon 1 (Fig.
2B). Interestingly, BCL6 binding to its own promoter was
enhanced (Fig. 2B) in spleens lacking PATZ (obtained from
Patz1 knock-outmice described below). The absence of immu-
noprecipitated PATZ in Patz1-null tissues confirmed the bind-
ing of PATZ to BCL6 exon 1 observed in the wild-type mice.
It is known that BCL6, by binding to its exon 1 and recruiting
the distal cis-acting factor ZEB1, represses its own transcrip-
tion, thus establishing a circuit of negative autoregulation (23,
24). To further investigate the role of PATZ in such a function
of BCL6, we used a reporter construct driving luciferase gene
expression under control of a BCL6 genomic sequence of 6.9
kb, including the ZEB1-responsive element, exon 1, and 1.5 kb
of intron 1 (BCL6i-luc) (18). Raji cells were co-transfected with
BCL6i-luc and plasmids expressing PATZ, BCL6, or both pro-
teins (Fig. 2C). As expected, BCL6 expression resulted in down-
regulation of the BCL6 promoter activity. A similar, but less
strong, activity was also achieved by PATZ, leading to a dose-
dependent repression of this BCL6 promoter region. Interest-
ingly, PATZ and BCL6 co-transfection resulted in the enhance-
ment of the BCL6-dependent repression (Fig. 2C). Western
blot analysis of Raji cells transfected or not with increasing
amounts of PATZ expression plasmid, as in Fig. 2C, confirmed
the negative dose-dependent effect of PATZ on BCL6 expres-
sion (Fig. 2D). To finally assess the dependence of BCL6 expres-
sion from PATZ, we analyzed, by Western blot, the BCL6 pro-
tein levels in mouse embryonic fibroblasts from Patz1$/$ and
Patz1#/# mice (described below). As shown in Fig. 2E, Patz1-
null mouse embryonic fibroblasts showed a significant increase
in BCL6 expression, which confirms the negative regulatory
role of PATZ on it.
Disruption of Mouse Patz1 Gene Causes Thymus B Cell
Expansion, Which Eventually Leads to B Cell Lymphomas—To
gain insights into the physiological role of PATZ in vivo, a tar-
geting vector was designed to knock out the mouse Patz1 gene
FIGURE 2.Role of PATZonBCL6promoter.A, ChIP analysis performedon Raji cells using specific anti-PATZ and anti-BCL6 polyclonal antibodies to detect the
endogenous in vivobinding of PATZ andBCL6 to exon 1of BCL6. The recoveredDNAwas used as a template for PCRwith primers that specifically amplify exon
1 of BCL6 or the promoter region of the LPL gene (negative control). input indicates PCR products with chromosomal DNA without immunoprecipitation.
Nonspecific IgGwas used as a negative control. B, ChIP assay, revealed by quantitative PCR, on spleens from Patz1$/$ and Patz1#/#mice to detect the binding
of PATZ and BCL6 proteins to exon 1 of Bcl6DNA. The percentage of immunoprecipitatedDNAwith respect to the input is reported. C, luciferase activity of the
BCL6 promoter (#4.9 to$2.0 kb) in Raji cells. Where indicated, 0.25 and 0.5 !g of PATZ and/or 5 !g of BCL6 expression vectors were co-transfected with the
BCL6i-luc plasmid. Where required, backbone vectors were also transfected to reach the same total amount of DNA for each experimental point. Data express
mean) S.D. of three independent experiments.Asterisks indicate the statistical results of amultiple comparison test versuspromoter basic activity. *, p( 0.05;
**, p( 0.01, ***, p( 0.001. D, representative Western blot analysis to detect BCL6 expression in Raji cells transfected or not with increasing amounts of PATZ
expression plasmid, as in C. As a control for equal loading, the same blot was incubated with antibodies against vinculin. E, Western blot analysis of BCL6
expression in mouse embryonic fibroblasts from Patz1$/$ and Patz1#/#mice. Vinculin has been analyzed as a loading control.
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by homologous recombination in ES cells (Fig. 3A). Inactivation
of the Patz1 allele was verified by analyzing Patz1 expression in
adult tissues using quantitative RT-PCR andWestern blot (Fig.
3, B and C). As expected, Patz1mRNA and protein were unde-
tectable in homozygous mutants, whereas they were present at
about half-levels in heterozygous as compared with wild-type
controls. Heterozygous mice were viable and fertile, but
heterozygous intercrosses produced viable homozygous
mutants at non-Mendelian frequencies. Indeed, the large
majority of homozygous mutants (about 75% on average) died
prenatally due to developmental defects in the cardiac outflow
tract.4 Here we focused on some phenotypes, observed in adult
mice (both heterozygous and homozygous for the Patz1-null
mutation), which can be due to an impaired regulation of the
BCL6 gene.
By 2–3 months of age, with a similar frequency (75%),
Patz1$/# and Patz1#/# mice develop thymus hyperplasias
characterized by focal expansion of an intramedullary B cell
population (Fig. 4A). B cells are the minority cell type (0.82 )
0.50%) in the thymus of wild-type animals, as confirmed by
FACS analysis in a cohort of 20 animals, but significantly
increase to an average of 5.94 ) 4.42 (p ( 0.05) in an equal
number of Patz1$/#mice (Fig. 4B). A similar increase of B cells
was also observed in Patz1#/#, where, for the limited number of
available animals, we could only do a qualitative analysis (data
not shown). To exclude that this B cell expansion could be due
to formation of intrathymic reactive B cell follicles possibly
induced by an altered CD4 helper versus cytotoxic subset ratio
(25), we analyzedCD4$ andCD8$ lymphocyte populations by
FACS in Patz1$/# thymi showing B cell hyperplasia, without
finding any differences in comparison with wild-type controls
(data not shown). Interestingly, in 4 out of 75 Patz1$/# mice
sacrificed at an advanced age (17–22 months old), we also
found thymus B cell lymphomas, characterized by large cells
with marked cell-to-cell variation in size and shape and abun-
dant pale cytoplasm, which were diagnosed as diffuse large B
cell lymphomas by our pathologists (Fig. 4C and data not
shown).
Thymus B Cell Lesions in Patz1 Knock-out Mice Are Depen-
dent on Bcl6 Expression—Pathological thymus B cells are con-
sidered to originate from the GC (26). Accordingly, focal
expression of BCL6 was detected in Patz1-knock-out thymus
lesions (either hyperplasia or lymphomas) but was absent in the
wild-type controls (Fig. 5A). Western blot analyses on thymus
tissues from Patz1$/#mice confirmed the expression of BCL6,
which was absent in Patz1$/$ controls (Fig. 5B). Up-regulation
of BCL6 in these cells is consistent with the role of PATZ in
BCL6 autoregulation (see above), which leads us to suggest that
decreased or null levels of PATZ causes up-regulation of BCL6
expression, which in turn could be responsible for the thymus
pathological phenotype. To validate our hypothesis of a role for
increased BCL6 expression in the development of certain phe-
notypes in Patz1 knock-out mice, we crossed Patz1$/# with
Bcl6$/# mice (27) to generate double mutants. Patz1#/#;
Bcl6$/$, Patz1$/$;Bcl6#/#, and Patz1#/#;Bcl6#/# mice died
during embryogenesis. However, because we observed the thy-
mus phenotype in Patz1 heterozygous mice, we analyzed the
alterations present in Patz1$/#;Bcl6$/$ mice and compared
them with the double heterozygous Patz1/Bcl6mutants.
Cohorts of 10 Patz1$/#;Bcl6$/$ and 10 Patz1$/#;Bcl6$/#
mice were equally distributed by gender and sacrificed at 12
months of age. Their thymus was analyzed by histological,
immunohistochemical, and FACS assays. As shown in Fig. 5C,
where representative FACS analyses are shown, 100% of the
Patz1$/#;Bcl6$/# mice analyzed did not show any significant
thymus B cell expansion as compared with the Patz1$/#;
Bcl6$/$ controls. Immunohistochemical analyses confirmed
this result in 80% of the cases, whereas in the remaining 20% of
double heterozygousmice, an aberrant thymus B cell hyperpla-
sia was observed, but it was strongly reduced as compared with
that observed in Patz1$/#;Bcl6$/$ mice (Fig. 5D). These
results confirm a key role for the up-regulation of BCL6 in the
pathological thymus phenotype of Patz1 knock-out mice.
Increased Tumorigenesis in Patz1 Knock-out Mice—Al-
though initially healthy, many adult Patz1$/# and most of the
few available Patz1#/# mice developed signs of morbidity and
displayed visible tumors as they aged. As evident in the survival
curves in Fig. 6A, Patz1#/# and Patz1$/# mice showed an
increased incidence of neoplastic lesions at %17 or 21 months
of age, respectively. Only 12% of the Patz1#/# and 67% of the
Patz1$/# animals were tumor-free at 20 months, in contrast to
the 95% of wild-typemice that were tumor-free at the same age.
The histological analyses revealed that 43 of 75 (57%)
Patz1$/# and 9 of 11 (82%) Patz1#/# mice developed malig-
nant tumors, versus only 7 of 63 (11%) wild-type mice. Patz1
knock-out tumors were mainly lymphomas, but hepatocellular
carcinomas and rare sarcomas and lung adenocarcinomas were
also detected. Wild-type animals developed lymphomas and
4 T. Valentino,D. Palmieri,M. Vitiello, A. Simeone, G. Palma, C. Arra, P. Chieffi, L.
Chiariotti, A. Fusco, and M. Fedele, manuscript submitted.
FIGURE3.GenerationofPatz1knock-outmice.A, schematic representation
of thewild-type andmutant alleles and the targeting vector. St, StuI; Sp, SpeI;
P, PstI; Ex., exon; Xb, XbaI. B and C, quantitative RT-PCR (B) and Western blot
analysis (C) in tissues from Patz1$/$, Patz1$/#, and Patz1#/#mice, to detect
PATZ expression and confirm its knock-out at both RNA and protein levels.
Data express mean) S.D. of three independent experiments.
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one hepatocellular carcinoma (Fig. 6B and data not shown).
Lymphomas from wild-type mice were all of the B cell lineage
but did not show BCL6 expression nor PATZ down-regulation
as compared with normal controls (data not shown).
To determine whether the tumors in Patz1$/# mice
occurred via loss of heterozygosity or haploinsufficiency, PATZ
protein expression and Patz1 gene sequence were analyzed in
the tumor tissues from Patz1$/# mice. Western blot (Fig. 6C)
and immunohistochemical analysis (data not shown) revealed
that PATZ was present in all of the tumors examined. Further-
more, sequence analysis of Patz1 cDNA isolated from eight
Patz1$/# tumors showed no mutation or rearrangement (data
FIGURE 4. Thymus neoplasias in Patz1 knock-outmice. A, immunohistochemical analysis in representative thymus sections of Patz1$/$ and Patz1$/#mice.
B220 staining shows thepresenceof a focal B cell hyperplasia in themedulla of themutant sample,whereas only scatteredB cellswere present in thewild-type
control. Scale bars, 100 !m. B, flow cytometry dot blots of the thymi showed in B stained with CD19 and CD5 antibodies. A distinct population of cells that
positively stains with CD19-PE antibody in the Patz1$/# (lower panel) is evident. No appreciable CD19$ cell population was found in the wild-type control
(upper panel). For each analysis, 10,000 events were counted. The relative percentage of CD19$ cells (B lymphocytes) was indicated in the right-bottom corner
of each dot plot. PE, Phycoerythrin. C, representative sample of a thymus B cell lymphoma developed by a Patz1$/#mouse. Left panels, hematoxylin and eosin
staining; right panels, immunostaining for B220. Scale bars, 100 !m.
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FIGURE5.KeyroleofBCL6 in thymusBcell expansionofPatz1knock-outmice.A, immunohistochemical stainingofBCL6 in representative thymus samples
from Patz1$/$ (left panel) and Patz1$/# (right panel) mice. Scale bar, 100!m. B, Western blot analysis for BCL6 expression in a pool of three Patz1$/$ and three
Patz1$/# thymi. C, flow cytometry of representative thymi from Patz1$/$;Bcl6$/$, Patz1$/#;Bcl6$/$, and Patz1$/#;Bcl6$/# mice. The thymocytes were double-
stained for specific B (CD19) and T cell (CD5) surface antigens. For each analysis, 10,000 eventswere counted. The relative percentageof CD19$ cells (B lymphocytes)
was indicated in the right-bottom cornerof eachdot plot.CD19-PE, CD19-Phycoerythrin staining.D, immunohistochemical analysis of the thymi shown inC to detect
B cells (stainedwith anti-B220). Only scatteredpositive cellswere detected inPatz1$/$;Bcl6$/$ (#,$) andmost Patz1$/#;Bcl6$/# thymi (%,&). Large focal hyperplasias
of B cells were detected in Patz1$/#;Bcl6$/$ (', () thymi, and small focal positivity was detected in some Patz1$/#;Bcl6$/# thymi (), *). Scale bars, 100!m.
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not shown). These results indicate that haploinsufficiency,
rather than loss of heterozygosity, accounts for the tumor
occurrence in Patz1$/# mice, thus suggesting Patz1 as a hap-
loinsufficient tumor suppressor gene.
Spleen lymphomas were the most representative malignant
diseases in Patz1 knock-out mice, and they were further char-
acterized to determine themechanism by which reduced Patz1
expression induces such neoplasias. Tumor sections from
Patz1$/# mice were stained with antibodies raised against T
cell- and B cell-specific markers to determine the cell type of
origin of the lymphoma. Interestingly, we found both B type
and T type lymphomas with a prevalence of B (28%) versus T
lymphomas (17%). The B type lymphoma (BCL) subtypes, as
defined by Morse et al. (28), were as follows: (a) diffuse large B
cell (16.8%), (b) follicular B cell (5.6%), (c) pre-B cell (2.8%), and
(d) small B cell lymphomas (2.8%) (Fig. 6D). Flow cytometry
analysis confirmed the immunohistochemical data (data not
shown). To further characterize lymphoid neoplasias, IgH gene
configuration was analyzed by Southern blot of EcoRI-digested
spleen DNA from Patz1$/$ and Patz1$/# mice using a probe
representing the JH4 region of the IgH locus (Fig. 6E). The
6.5-kb fragment represents the germ line configuration of the
gene. All BCLs showed oligoclonal rearrangements of the germ
line IgH joining region (Fig. 6E, asterisks). Interestingly, benign
lymphoproliferative diseases often showaberrantV(D)J recom-
bination at the IgH locus, suggesting that theymay represent an
FIGURE 6. Increased lymphomagenesis in Patz1 knock-out mice. A, Kaplan-Meyer tumor incidence analysis of Patz1$/$, Patz1$/#, and Patz1#/# mice.
Cohorts of 63 wild-type, 75 heterozygous, and 11 homozygous Patz1 knock-out mice were monitored and harvested when they exhibited symptoms of
disease. The curveswere significantly different (p(0.0001) as determinedby log rank test.B, the lymphoidphenotype, as a functionof the relativepercentage,
in mice homozygous and heterozygous for the Patz1-null mutation versuswild-type controls was plotted as pie charts. The number of mice analyzed for each
genotype is the same as in A. C, Western blot analysis showing expression of BCL6 and PATZ in spleen samples from Patz1$/$ and Patz1$/#mice. #-Tubulin
expressionwas evaluated as a loading control.N, normal;Hy, hyperplasia; Ly, lymphoma.D, immunohistochemical staining for thephenotypic characterization
of lymphomas in Patz1 knock-out mice. Representative Patz1$/# spleen samples of all types of lymphomas observed are shown (for the percentage of each
type, see under “Results”). Antibodies used for the staining are indicated on the top. H&E, hematoxylin and eosin staining; DLBCL, diffuse large cell B cell
lymphoma; TCL, T cell lymphoma; pre-BCL, pre-B cell lymphoma; FBL, follicular B cell lymphoma; SBL, small B cell lymphoma. Scale bars, 100 !m. E, IgH gene
rearrangements were analyzed by Southern blot on EcoRI-digested spleen DNA. Control ($/$) is the wild-type mouse with the genomic 6.5-kb fragment
representing thegene in its germ line configuration.All hyperplastic (Hy) andBcell lymphomasamples fromPatz1$/#mice, andnormal spleen fromaPatz1#/#
mouse, show rearranged extra bands (asterisks). The histological diagnoses of the spleens are indicated above.
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early stage in the development of BCLs. The same Southern
blotwas also probed for gapdh, which gave rise to a unique band
for all loaded samples (data not shown). Both BCLs and lym-
phoproliferative diseases expressed BCL6, whereas it was not
detectable in wild-type controls or normal spleens from Patz1
knock-out mice (Fig. 6C), suggesting a key role for this onco-
protein in development of such neoplasias.
DISCUSSION
Previous studies suggest a cancer-related role for PATZ (3,
8–11), but the mechanisms by which PATZ is involved in the
process of carcinogenesis are still controversial. Our data indi-
cate that PATZ acts as a tumor suppressor in lymphomagenesis
by inhibiting BCL6 expression.We first showed that PATZ and
BCL6 bind to each other. This finding is consistent with the
notion that POK proteins, such as PATZ and BCL6, commonly
aggregate in large nuclear complexes by self-interaction, as het-
erodimers with other POK proteins and in association with
unrelated partners, such as transcriptional corepressors, as a
way to extend the repertoire of their target genes and/or the
ways they act on their expression (29). BCL6 is the most com-
monly altered proto-oncogene in non-Hodgkin lymphomas,
the majority of which derive from normal GC B cells (30). In
fact, its sustained expression causes malignant transformation
of GC B cells (31). Nearly half of human diffuse large B cell
lymphomas, the most common form of non-Hodgkin lympho-
mas, express BCL6 constitutively, mainly as a consequence of
BCL6 gene rearrangements and activating pointmutations that
target the 5" regulatory region of this gene (23, 24, 32, 33). How-
ever, different studies showed that BCL6 expression in lym-
phoma is largely independent from the corresponding chromo-
somal alterations, suggesting that mechanisms other than gene
rearrangements or mutations can deregulate its expression in
lymphomas (34, 35). BCL6 expression is tightly regulated in a
lineage- and developmental-stage-specificmanner, and disrup-
tion of normal controls can contribute to lymphomagenesis
(13, 14, 36). Transcription of the BCL6 gene is negatively self-
regulated bymeans of the interaction of two BCL6 binding sites
within exon 1 of the gene and the BCL6 protein itself, which is
a potent transcription repressor, and both chromosomal trans-
locations and activating mutations allow lymphoma cells to
bypass this negative autoregulation mechanism (23, 24). To
date, a variety of corepressors have been described. Among
them, the CtBP1 and ZEB1 transcriptional repressors are
required for BCL6 autoregulation (18, 37). In a recent model, a
repressive complex at the BCL6 locus that involves binding of
transcription factors to both exon 1 and a distant cis-acting
element (HSS-4.4) has been suggested to regulate BCL6 tran-
scription. In this complex, ZEB1 and BCL6, which bind to dis-
tant sites, are linked through binding of the common corepres-
sor CtBP1 (18). In the present study, we show that PATZ can
bind BCL6 exon 1 and negatively modulate BCL6 promoter
activity. Therefore, we speculate that PATZ can be one of the
transcription factors involved in the complex and that, because
of its ability to bind theminor groove ofDNAvia theAT-hooks,
could be crucial for the bending of DNA required to put
together distant cis-acting transcription factors. Because PATZ
can interact and cooperate with BCL6, we can suggest that it
acts together with BCL6 in its autoregulation. However, we
cannot exclude that PATZ can also act without BCL6, thus
contributing to keep BCL6 expression off when BCL6 is not
expressed at all. Consistent with a role of PATZ in BCL6 nega-
tive regulation, we also show thatmice carrying a null mutation
of the Patz1 gene develop an aberrant expansion of thymus B
cells, inwhichBCL6 expression is up-regulated.Webelieve that
this phenotype, which we demonstrated to be dependent on
BCL6 expression, is also responsible for the development of
BCLs thatwe observe in both thymi and spleens of Patz1 knock-
out mice at a later age.
In conclusion, our data indicate a haploinsufficient tumor
suppressor role for PATZ that would act in lymphomagenesis
by down-regulating BCL6 expression.
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(PATZ) interacts with human oncogene B cell lymphoma
6 (BCL6) and is required for its negative autoregulation.
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PAGE 18315:
Western blot images representing PATZ, BCL6, and tubulin in Fig.
6C did not accurately represent the experimental results. Different lanes
were erroneously duplicated. Lane 3 of the PATZ panel was duplicated
in lane 7; lane 4 of the PATZ panel was duplicated in lanes 5 and 6; lane
1 of the BCL6 panel was duplicated in lane 2; lane 4 of the tubulin panel
was duplicated in lane 7; and lane 5 of the tubulin panel was duplicated
in lane 6. The authors have provided an image from a replicate experi-
ment. This correction does not affect the interpretation or conclusions
of this work.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 289, NO. 21, p. 14966, May 23, 2014
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
14966 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 21•MAY 23, 2014
ADDITIONS AND CORRECTIONS
Authors are urged to introduce these corrections into any reprints they distribute. Secondary (abstract) services are urged to carry notice of
these corrections as prominently as they carried the original abstracts.
Lorenzo Chiariotti and Monica Fedele
Wagner, Carlo M. Croce, Alfredo Fusco,
Arra, Vasiliki Papadopoulou, Simon D. 
Donatella Montanaro, Simona Keller, Claudio
Andres J. Klein-Szanto, Luigi Del Vecchio, 
Federico, Renato Franco, Francesca Lembo,
Angrisano, Teresa Valentino, Antonella 
Raffaela Pero, Dario Palmieri, Tiziana
  
Autoregulation
(BCL6) and Is Required for Its Negative 
6with Human Oncogene B Cell Lymphoma 
InteractsFinger-containing Protein (PATZ) 
POZ-, AT-hook-, and Zinc
Gene Regulation:
doi: 10.1074/jbc.M112.346270 originally published online April 9, 2012
2012, 287:18308-18317.J. Biol. Chem. 
  
 10.1074/jbc.M112.346270Access the most updated version of this article at doi: 
  
.JBC Affinity SitesFind articles, minireviews, Reflections and Classics on similar topics on the 
 Alerts: 
  
 When a correction for this article is posted•  
 When this article is cited•  
 to choose from all of JBC's e-mail alertsClick here
  
 http://www.jbc.org/content/287/22/18308.full.html#ref-list-1
This article cites 38 references, 17 of which can be accessed free at
 at UNIV OF NAPLES on January 19, 2015
http://www.jbc.org/
Downloaded from 
